人福医药(600079.SH)：奥卡西平缓释片获美国FDA暂定批准文号

Core Viewpoint - The company, Renfu Pharmaceutical, announced that its subsidiary, Wuhan Renfu Likang Pharmaceutical Co., Ltd., received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine extended-release tablets, which are used to treat partial seizures in patients aged 6 years and older [1]. Group 1 - The FDA's tentative approval indicates a significant milestone for the company in expanding its product offerings in the U.S. market [1]. - Oxcarbazepine extended-release tablets are specifically indicated for the treatment of partial seizures, highlighting the company's focus on addressing neurological conditions [1].